EA200600675A1 - Гранулы, содержащие гидрохлорид венлафаксина - Google Patents

Гранулы, содержащие гидрохлорид венлафаксина

Info

Publication number
EA200600675A1
EA200600675A1 EA200600675A EA200600675A EA200600675A1 EA 200600675 A1 EA200600675 A1 EA 200600675A1 EA 200600675 A EA200600675 A EA 200600675A EA 200600675 A EA200600675 A EA 200600675A EA 200600675 A1 EA200600675 A1 EA 200600675A1
Authority
EA
Eurasian Patent Office
Prior art keywords
granules
granules containing
hydrochloride
venlafaxine hydrochloride
weight
Prior art date
Application number
EA200600675A
Other languages
English (en)
Other versions
EA009695B1 (ru
Inventor
Паль Фекете
Тибор Корбей
Агнеш Божо
Эстер Мориц
Original Assignee
Эгиш Дьёдьсердьяр Рт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Рт. filed Critical Эгиш Дьёдьсердьяр Рт.
Publication of EA200600675A1 publication Critical patent/EA200600675A1/ru
Publication of EA009695B1 publication Critical patent/EA009695B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к гранулам, содержащим гидрохлорид венлафаксина и способу их приготовления. Гранулы в соответствии с изобретением имеют форму, близкую к сферической, и включают фармацевтически активный гидрохлорид венлафаксина в количестве максимум 80% по массе, кроме того, от 10 до 60% по массе хлорида натрия и/или хлорида калия, от 10 до 60% по массе микрокристаллической целлюлозы и возможно других фармацевтически приемлемых эксципиентов и/или добавок, способствующих грануляции. Указанные гранулы особенно подходят для покрытия слоем, обеспечивающим контролируемое высвобождение активного ингредиента.
EA200600675A 2003-10-10 2004-10-08 Гранулы, содержащие гидрохлорид венлафаксина EA009695B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride

Publications (2)

Publication Number Publication Date
EA200600675A1 true EA200600675A1 (ru) 2006-08-25
EA009695B1 EA009695B1 (ru) 2008-02-28

Family

ID=90001704

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600675A EA009695B1 (ru) 2003-10-10 2004-10-08 Гранулы, содержащие гидрохлорид венлафаксина

Country Status (23)

Country Link
EP (1) EP1677777B1 (ru)
CN (1) CN1882321B (ru)
AT (1) ATE359771T1 (ru)
AU (1) AU2004280132B2 (ru)
BG (1) BG109539A (ru)
CY (1) CY1106693T1 (ru)
CZ (1) CZ2006269A3 (ru)
DE (1) DE602004006009T2 (ru)
DK (1) DK1677777T3 (ru)
EA (1) EA009695B1 (ru)
ES (1) ES2285538T3 (ru)
HK (1) HK1098364A1 (ru)
HR (2) HRP20060136A2 (ru)
HU (1) HUP0303382A2 (ru)
IL (1) IL174830A (ru)
NO (1) NO20062082L (ru)
PL (2) PL1677777T3 (ru)
PT (1) PT1677777E (ru)
RS (2) RS52150B (ru)
SI (1) SI1677777T1 (ru)
SK (1) SK50442006A3 (ru)
UA (1) UA82268C2 (ru)
WO (1) WO2005034930A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2007016315A2 (en) * 2005-07-28 2007-02-08 Dr. Reddy's Laboratories Ltd. Extended release venlafaxine compositions
EP2023903B1 (en) * 2006-05-19 2014-04-23 EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság Process for the preparation and surface coating of pellets
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
MX2012013023A (es) * 2010-05-11 2012-12-17 Cima Labs Inc Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
WO2014096124A1 (en) * 2012-12-19 2014-06-26 Ratiopharm Gmbh Film coated pellets
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
CN114028577B (zh) * 2021-10-20 2024-07-02 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations

Also Published As

Publication number Publication date
PT1677777E (pt) 2007-06-21
HUP0303382A2 (hu) 2005-08-29
ATE359771T1 (de) 2007-05-15
EP1677777B1 (en) 2007-04-18
HRP20060136A2 (en) 2006-06-30
HRP20070322T3 (en) 2007-09-30
CY1106693T1 (el) 2012-05-23
AU2004280132A1 (en) 2005-04-21
DE602004006009T2 (de) 2008-01-10
CZ2006269A3 (cs) 2006-07-12
CN1882321A (zh) 2006-12-20
NO20062082L (no) 2006-05-09
HK1098364A1 (en) 2007-07-20
SK50442006A3 (sk) 2006-08-03
DE602004006009D1 (de) 2007-05-31
RS52150B (en) 2012-08-31
ES2285538T3 (es) 2007-11-16
EA009695B1 (ru) 2008-02-28
PL379541A1 (pl) 2006-10-02
EP1677777A1 (en) 2006-07-12
UA82268C2 (ru) 2008-03-25
CN1882321B (zh) 2011-06-08
RS20060252A (en) 2008-08-07
WO2005034930A1 (en) 2005-04-21
DK1677777T3 (da) 2007-09-03
AU2004280132B2 (en) 2009-10-22
HUP0303382D0 (en) 2003-12-29
IL174830A (en) 2010-04-15
IL174830A0 (en) 2008-04-13
BG109539A (bg) 2006-11-30
SI1677777T1 (sl) 2007-10-31
PL1677777T3 (pl) 2007-08-31

Similar Documents

Publication Publication Date Title
IL174830A0 (en) Pellets containing venlafaxine hydrochloride, pharmaceutical compositions comprising them and processes for their preparation
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HK1091137A1 (en) Extended release coated minitablets of venlafaxinehydrochloride
HK1072359A1 (en) Pharmaceutical composition comprising N-((1-N-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-A)indole-10carboxamide or salt and process for preparing thereof comprising dry granulation
ATE331525T1 (de) Salzformarme polyallylamine
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
HUP0302631A2 (hu) Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.
JP2011516544A5 (ru)
BRPI0507765A (pt) comprimidos revestidos compressos e sua produção
RU2006145311A (ru) Твердая фармацевтическая композиция
EA200500175A1 (ru) Соль морфин-6-глюкуронида
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
TW200631600A (en) Hair fitness/body improving agent and hair cosmetic
TNSN06242A1 (en) Extended release coated minitablets of venlafaxine hydrochloride

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU